



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/413,110	10/06/1999	EVAN C. UNGER		1596

7590 11/16/2006  
EVAN C. UNGER  
6227 E. MIRAMAR STREET  
TUCSON, AZ 85710

EXAMINER

COTTON, ABIGAIL MANDA

ART UNIT	PAPER NUMBER
----------	--------------

1617

DATE MAILED: 11/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/413,110

Applicant(s)

UNGER, EVAN C.

Examiner

Abigail M. Cotton

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 23 May 2006 and 24 August 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-250 is/are pending in the application.
- 4a) Of the above claim(s) 180-250 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 116-131, 138-141, 146-151, 160, 164-166, 168-174, 178 and 179 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                 | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date: _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                        | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 23, 2006 has been entered.

Claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-250 are pending in the application, with claims 180-250 having been withdrawn as drawn to a non-elected species of invention. Accordingly, claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are being examined on the merits herein.

The rejection of the claims under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,380,411 to Schlieff in view of the article to Holmes et al. is being withdrawn, as the references do not teach or suggest the administration of the elected species of bioactive agent that is a thrombolytic agent, as recited in the claims.

The rejection of the claims under 35 U.S.C. 103(a) over U.S. Patent No. 5,695,460 to Siegel et al. in view of U.S. Patent No. 5,648,098 to Porter are being

Art Unit: 1617

withdrawn, as the references do not specifically teach providing the elected species of lipids that are phospholipids as a part of the vesicles.

The claims are rejected as set forth below.

### ***Election/Restrictions***

The Examiner notes that the claims are being examined to the extent they read on the elected species of bioactive agent that are thrombolytic agents, as elected by Applicants on May 7, 2001, as well as the elected species of gas or gaseous precursor that is perfluorobutane, vesicles comprising phospholipids, target tissue that comprises an area of reduced blood perfusion, and a rate of administration that is from  $1 \times 10^6$  to about  $8 \times 10^6$  vesicles/Kg-sec, as elected in the same response. Accordingly, claims 185-250, drawn to non-elected species of bioactive agents, are withdrawn from examination.

The Examiner furthermore notes that claims 180-184 are drawn to methods involving the application of radiation energy, which methods do not correspond to methods involving the elected species of bioactive agent that is a thrombolytic agent, and instead correspond to methods involving the administration of, for example, an anti-tumor drug. Accordingly, claims 180-184 are withdrawn from examination as

Art Unit: 1617

corresponding to a non-elected species of invention, pending a finding of allowability of a generic or linking claim.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In particular, the specification as originally filed does not specifically disclose "delivering said bioactive agent from the vasculature through the vessel wall and into said selected tissue by cavitation and/or rupturing said vesicles," as recited for example in claim, or "delivering said bioactive agent from the vasculature through the vessel wall and into said selected tissue by activating said acoustically active composition" by "applying to the patient ultrasonic energy," as recited in claim 164.

The specification discloses for example that "vesicles may be ruptured using ultrasound to release the bioactive agent in the region" (see page 87), and discloses a

Art Unit: 1617

specific method of treating a tumor in which vesicles and a Carmustine are intravenously supplied, followed by ultrasonic energy application, in which it is disclosed that "the patient will receive enhanced delivery of the drug into the tumor tissue due to cavitation enhanced drug permeation caused by interaction of the ultrasound with the gas filled vesicles" (see page 97.) Thus, the specification teaches that bioactive agent, in general can be delivered by cavitation of drug-containing vesicles, and also teaches that permeation of an anti-tumor drug in tissue can be improved by applying ultrasound.

However, the specification does not teach that the cavitation of the vesicles or the application of ultrasonic energy is itself responsible for the delivery of the bioactive agent from the vasculature and into said selective tissue, or that such energy application/cavitation itself causes transport through the vessel wall, as recited in the claims. In contrast, the specification only teaches the ability of the vesicles to delivery a drug upon cavitation (i.e., the vesicles break open with ultrasonic energy and release the drug), or to increase permeation of a drug in tissue, such as to increase the permeation of a drug deeper into tissue in which the drug has already penetrated. The specification is silent on the ability of ultrasonic energy/cavitation to affect the transport of drugs through a vessel wall or to specifically cause the transport of a drug into tissue from vasculature. Accordingly, the amendments to the claims introduce impermissible new matter in the application, and are rejected under 35 U.S.C. 112, first paragraph. Claims 117-131, 138-141, 146-151, 160, 165-166, 168-174 and 178-179 are rejected as being dependent upon claims having new matter.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 116-125, 129-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are rejected under 3 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,695,460 to Siegel et al, issued December 9, 1997, in view of U.S. Patent No. 5,334,381 to Evan C. Unger, issued August 2, 1994, and further in view of U.S. Patent No. 5,648,098 to Thomas R. Porter, issued July 15, 1987.

Siegel et al. teaches a method that utilizes a combination of ultrasonic agent and echo contrast agent containing microbubbles, for substantially dissolving blood clots or other vascular obstructions (see abstract, in particular.) Siegel et al. teaches that the application of the ultrasonic energy to the microbubble is capable of dissolving arterial thrombi (see column 1, line 65 through column 2, line 8, in particular.) Siegel et al. teaches that a thrombolytic agent can be introduced proximate the thrombosis to further enhance the clot dissolution (see column 2, lines 1-18, in particular), and thus teaches administering a bioactive agent corresponding to the elected species of thrombolytic

Art Unit: 1617

agent to said patient, as recited in part (i) of claims 116 and 164. Siegel et al. teaches that the contrast agent, such as the microbubbles, can be injected into an occluded vessel, and thus teaches the intravascular infusion of a vesicle/acoustically active composition into the patient, as recited in part (ii) of claims 116 and 164.

Siegel et al. teaches that the echo contrast agent can be, for example, a dodecafluoropentane colloidal dispersion (see column 2, lines 44-47, in particular), and further teaches that various types of microbubble media may be used for the echo contrast agent, including gas filled liposomes, gas filled lipid bilayers, gas-filled microspheres, etc (see column 5, lines 30-50, in particular.) Siegel et al. teaches a preferred contrast agents are Echogen and sonicated human serum albumin (see column 5, line 50-55, in particular.) Thus, Siegel et al. teaches administering the vesicles as recited in claims 116 and the acoustically active composition, as recited in claim 164.

Siegel et al. teaches that the ultrasonic energy is applied to the microbubbles, increased cavitation of the vascular fluid surrounding the thrombosis is achieved, thus reducing or removing the thrombosis (see column 5, line 55 though column 6, line 4, in particular.) Accordingly, Siegel et al. teaches applying to the patient an ultrasonic energy to activate and/or cavitate and/or rupture the vesicles, as recited in part (iii) of claims 116 and 164. Siegel et al. teaches that a suitable frequency of the ultrasonic energy may be from 25 and up to 100 kHz (see column 5, lines 29-40, in particular.)



Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the frequency of the ultrasonic radiation applied to the patient, according to the guidance provided by Siegel et al, to achieve the desired therapeutic effects, such as the desired dissolution of the thrombi. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

The Examiner furthermore notes that the range of ultrasonic energy frequencies taught by Siegel et al. fails within the range that is disclosed by Applicants on page 68 of the instant specification (0.025 to 100 MHz) as being suitable for the cavitation/rupturing of the vesicles, and thus it is considered that the frequency of Siegel et al. also necessarily causes the cavitation/rupturing of the microbubbles.

Siegel et al. does not specifically teach a method in which the vesicles comprise the elected species of lipid that is phospholipids and elected species of gas that is perfluorobutane. Siegel et al. also does not specifically teach applying the recited ultrasonic frequency of between about 750 kHz and 3 MHz, as recited in claims 116 and 164.

Unger teaches liposomes suitable as ultrasound contrast agents having liposomes encapsulated therein (see abstract, in particular), and thus teaches gas-filled

Art Unit: 1617

liposomes. Unger teaches that suitable contrast agent can comprise liposomes formed from lipids such as phosphatidylcholine, phosphatidylethanolamine, etc (see column 9, lines 15-40, in particular), and thus teaches providing lipids corresponding to the elected species of phospholipids to form the gas filled liposomes.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the phospholipids-containing liposomes of Unger in the composition and method of Siegel et al, because Siegel teaches that the composition can comprise ultrasound echo contrast agents comprising gas-filled liposomes, and teaches administering the contrast agents to reduce and remove thrombi, and Unger teaches that gas-filled liposomes can be formed from phospholipids to provide ultrasound contrast agents. Thus, one of ordinary skill in the art would have been motivated to provide gas-filled phospholipid liposomal contrast agents in the composition and method of Siegel et al, with the expectation of providing a suitable ultrasound contrast agent capable of use in the reduction and removal of thrombi.

Siegel et al. and Unger do not specifically teach a method in which the vesicles comprise the elected species of gas that is perfluorobutane. Siegel et al. and Unger also does not specifically teach applying the recited ultrasonic frequency of between about 750 kHz and 3 MHz, as recited in claims 116 and 164, or the specific elected species of administration rate.

Porter teaches a microbubble preparation and thrombolytic therapy therewith, in which the microbubbles are intravenously injected and are caused to cavitate by the application of an applied ultrasound field in the vicinity of the thrombus, thereby removing the clot (see abstract, in particular.) Thus, Porter teaches cavitating and/or rupturing microbubbles via application of ultrasound energy in the vicinity of a thrombus to provide thrombolytic effects. Porter teaches that the microbubbles can contain an internal atmosphere, such as a fluorocarbon gas, including perfluorobutane (see abstract, column 2, lines 20-35 and column 3, lines 20-35, in particular), and thus teaches providing microbubbles having the elected species of gas that is perfluorobutane.

Porter teaches that a desired ultrasonic energy to achieve the cavitation can be as little as 20 KHz to several MHz, such as from 3 to 5 MHz (see column 4, lines 45-50, in particular), and thus teaches a frequency range that overlaps as claimed. Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the frequency of the ultrasonic radiation applied to the patient, according to the guidance provided by Siegel et al. and Porter, to achieve the desired therapeutic effects, such as the desired dissolution of the thrombi. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges

Art Unit: 1617

by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Regarding the elected species of rate of vesicle administration, Porter teaches that an anti thrombosis therapy can comprise administering from 0.0025 to 0.1 mg/kg of therapeutic composition over about 1 to 25 minutes (see Example 2, in particular), where the microbubble concentration may be between  $0.8 \times 10^9$  and  $1.5 \times 10^9$  per each milliliter (see column 6, lines 33-36, in particular.) Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the rate of delivery of the treatment agent, according to the guidance provided by Siegel et al, Unger and Porter, to achieve the desired therapeutic effects. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to apply the ultrasonic frequencies of Porter in the method of Siegel et al. and Unger, because Siegel et al. teaches applying ultrasonic energy to the microbubbles to increase cavitation and remove or reduce the thrombus, whereas Porter teaches frequencies of ultrasonic energy that are suitable for achieving cavitation and the lysis of thrombi. Thus, one of ordinary skill in the art would

have been motivated to apply the frequencies of Porter in the method of Siegel et al. and Porter, with the expectation of achieving a reduction and/or removal of the thrombus.

It is furthermore considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the perfluorobutane gas of Porter in the composition and method of Siegel et al. and Unger, and to administer the composition at the rate taught by Porter, because Siegel et al. and Unger teach that the composition can comprise gas filled microbubbles, such as gas-filled liposomes, and teach administering the microbubbles to reduce and remove thrombi, and Porter teaches that perfluorobutane is a gas suitable for microbubble cavitation treatment of thrombi, and teaches rates of therapeutic composition delivery that are suitable for the reduction and/or removal of the thrombi. Thus, one of ordinary skill in the art would have been motivated to provide the perfluorobutane in the gas-filled microbubbles/liposomes of Siegel et al. and Unger, and to administer the microbubbles at the rate taught and/or rendered obvious by Porter, with the expectation of providing microbubbles and a microbubble administration rate capable of being ultrasonically cavitated to reduce and/or remove thrombi.

Regarding the recitation that the method is "for the delivery of a bioactive agent from the vasculature to a selected tissue in a patient" as recited in claims 116 and 164, it is noted that the recitation of an intended use of the claimed invention must result in a

structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963.) Thus the intended use recited in claim 1, namely that the method is for "the delivery of a bioactive agent from the vasculature to a selected tissue in a patient," is not afforded patentable weight.

Regarding the recitation of "delivering said bioactive agent from the vasculature through the vessel wall and into said selected tissue by cavitation and/or rupturing said vesicles" as in claim 116, or "by activating said acoustically active composition" as in claim 164, it is noted that as Siegel et al, Unger and Porter render obvious the same method steps as instantly claimed, namely the delivery of active agents and microbubbles and the application of ultrasonic energy in the frequency range to rupture and/or cavitate the microbubbles to remove thrombi, it is considered that the method necessarily also causes the delivery of the bioactive agent from the vasculature into the tissue of the patient. It is respectfully pointed out that a recitation of an intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. In a claim drawn to a process, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ

Art Unit: 1617

(CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963.) Thus the intended use recited in claims 116 and 164, namely that the application of ultrasonic energy causes the delivery of the bioactive agent into the tissue, is considered to be taught by the combination of Siegel et al, Unger and Porter.

Accordingly, claims 116 and 164 are obvious over the teachings of Siegel et al, Unger and Porter.

Regarding claims 117 and 165, Porter teaches infusion over 1-25 minutes (see column 7, lines 60-66, in particular), and thus is considered to teach continuous infusion, as recited in the claim. Regarding claims 118 and 166, Siegel et al. teaches that a combination of echo contrast agent (e.g. microbubbles) and thrombolytic agent or disruptive agent can be injected proximate a thrombosis disposed in a vessel in the body (see column 3, lines 14-20, in particular), and thus is considered to teach administration of the vesicle composition and thrombolytic agent substantially simultaneously, as recited in the claim. Regarding claims 119 and 173, Siegel et al. teaches that it is known to use ultrasonic imaging to locate and image intravascular thrombi (see column 1, lines 10-20, in particular), and thus it is considered that it would be obvious to combine ultrasonic imaging with the method taught therein to image the thrombi before and/or after treatment.

Regarding claims 120-123, Unger teaches that the ultrasound imaging vesicles can be formed of liposomes containing phospholipids such as phosphatidylcholine, phosphatidylethanolamine, etc (see column 9, lines 15-40, in particular.) Regarding claims 124-125, Unger teaches providing dipalmitoylphosphatidylcholine (see column 10, lines 20-30, in particular.) Regarding claims 129-131, Unger teaches that the surface of the liposome can be modified by incorporating a polymer such as polyethylene glycol (see column 9, lines 30-40, in particular.)

Regarding claims 138-141, Porter renders obvious providing perfluorobutane as the gas incorporated in the liposomes, as discussed above. Regarding claims 146-151, the teachings of Siegel et al, Unger and Porter render obvious providing the composition at the rate corresponding to the elected species. Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the rate of administration of the composition, according to the guidance provided by Siegel et al, Unger and Porter, to provide the desired therapeutic treatment. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Regarding claims 160 and 174, Siegel et al. teaches providing a thrombolytic agent, as recited in the claim.



Regarding claims 168-172, Siegel et al. teaches treating a thrombus, as discussed above, which is a blood clot that can cause reduced blood perfusion in an area as well as ischemic tissue, including in the myocardium and in glandular tissue, such as in the prostate gland. Accordingly, it would be obvious over the teachings of the references to provide treatment of tissue affected by the presence of thrombi, and including those tissue types recited in the claims.

Regarding claims 178-179, Siegel et al. teaches that the treatment composition can be administered and subsequently, the ultrasound radiation can be applied (see column 5, lines 15-25, in particular.) However, it is also noted that the apparatus of Siegel et al, as displayed in Figure 1, allows for administering the treatment agent and ultrasound application "at about the same time", as recited in the claim, and thus it is considered that one of ordinary skill in the art would have found it obvious to intravenously introduce the composition proximate to the clot and very shortly thereafter apply ultrasound such that the application occurs at "about the same time." Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of time delayed between providing the composition and applying ultrasound energy, according to the guidance provided by Siegel, Unger and Porter, to provide a desired treatment method. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges

by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Claims 126-128 are rejected under 3 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,695,460 to Siegel et al, issued December 9, 1997, in view of U.S. Patent No. 5,334,381 to Evan C. Unger, issued August 2, 1994 (hereinafter Unger '381), and further in view of U.S. Patent No. 5,648,098 to Thomas R. Porter, issued July 15, 1987, as applied to claims 116-125, 129-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 above, and further in view of U.S. Patent No. 5,542,935 to Unger et al, issued August 6, 1996 (hereinafter Unger et al. '935.)

Siegel et al, Unger '381 and Porter are applied as discussed above, and teach a method of reducing thrombi by applying ultrasound energy to a contrast agent that can comprise a gas-filled liposome, such as a liposome formed from a phospholipids, such as phosphatidylcholine.

The references do not specifically teach that the liposome can comprise phospholipids such as dipalmitoylphosphatidylethanolamine and/or dipalmitoylphosphatidic acid, as recited in claims 126-128.

Unger et al. '935 teaches gaseous precursor filled microspheres for therapeutic applications (see abstract, in particular.) Unger et al. '935 teaches that the

microspheres can be used in imaging techniques, such as ultrasound imaging (see column 1, lines 63-67, in particular), and can comprise liposome microspheres formed from phospholipids such as phosphatidylethanolamines and phosphatidic acid (see column 20, lines 61 through column 21, line 20, in particular), such as dipalmitoylphosphatidylethanolamine (see column 22, lines 15-20, in particular.) Unger et al. exemplifies forming such an agent by entrapping perfluoropentane gas in a liposome formed from dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine and dipalmitoylphosphatidic acid (see column 9, lines 30-40, in particular), and thus teaches providing the phospholipids as claimed for the formation of gas-filled liposomes suitable for ultrasonic imaging applications.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the specific phospholipid-containing liposomes of Unger et al. '935 in the composition and method of Siegel et al, Unger '381 and Porter, because Siegel et al, Unger '381 and Porter teach that the composition can comprise ultrasound echo contrast agents comprising gas-filled liposomes, and teaches administering the contrast agents to reduce and remove thrombi, and Unger et al. '935 teaches that gas-filled liposomes can be formed from the specific phospholipids as claimed to provide ultrasound contrast agents. Thus, one of ordinary skill in the art would have been motivated to provide gas-filled phospholipid liposomal contrast agents in the composition and method of Siegel et al, Unger '381 and

Porter, with the expectation of providing a suitable ultrasound contrast agent capable of use in the reduction and removal of thrombi.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-77 of U.S. Patent No. 6,576,220. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to a method involving administering a bioactive agent comprising a

Art Unit: 1617

thrombolytic agent, administering a vesicle composition intravascularly, and applying ultrasound energy at a specific frequency to rupture or cavitate the vesicles, whereas the conflicting patented claims are to intravascularly administering the vesicles and applying ultrasound energy to rupture the vesicles, where the vesicles can be applied with a bioactive agent, and can be used for the treatment of a thrombus. The conflicting claims also recited the elected species of phospholipids and fluorocarbon gas. The conflicting claims differ from those of the instant case in that they do not recite the specific frequency of ultrasound energy. However, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the frequency of the ultrasound energy applied. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.) Accordingly, the instant claims are not patentably distinct from those in the 6,576,220 patent.

Claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 6,716,412. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to a method involving administering a bioactive agent comprising a thrombolytic agent, administering a vesicle composition intravascularly, and applying ultrasound energy at a specific frequency to rupture or cavitate the vesicles, whereas

Art Unit: 1617

the conflicting patented claims are to administering the vesicles and applying ultrasound energy to rupture the vesicles, where the vesicles can be applied with a bioactive agent, and can be used for the treatment of a blood clot. The conflicting claims also recited the elected species of phospholipids and fluorocarbon gas. The conflicting claims differ from those of the instant case in that they do not recite the specific frequency of ultrasound energy. However, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the frequency of the ultrasound energy applied. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.) Accordingly, the instant claims are not patentably distinct from those in the 6,716,412 patent.

Claims 116-131, 138-141, 146-151, 160, 164-166, 168-174 and 178-179 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-42 of U.S. Patent Application Publication No. 2004/0265393. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to a method involving administering a bioactive agent comprising a thrombolytic agent, administering a vesicle composition intravascularly, and applying ultrasound energy at a specific frequency to rupture or cavitate the vesicles, whereas the conflicting published claims are to intravascularly administering the vesicles and applying ultrasound energy to rupture the

Art Unit: 1617

vesicles, where the vesicles can be applied with a bioactive agent, and can be used for the treatment of a blood clot. The conflicting claims also recited the elected species of phospholipids and fluorocarbon gas. The conflicting claims differ from those of the instant case in that they do not recite the specific frequency of ultrasound energy.

However, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the frequency of the ultrasound energy applied. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.) Accordingly, the instant claims are not patentably distinct from those in the 2004/0265393 publication.

### ***Response to Arguments***

Applicant's arguments with respect to the rejections of the claims have been considered but are moot in view of the new ground(s) of rejection.

### ***Conclusion***

No claims are allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. U.S. Patent No. 5,197,946 to Shunro Tachibana, issued March


Art Unit: 1617

30, 1993, teaches that application of ultrasonic energy enhances diffusion and penetration of a medicinal medium into body tissue, such as in the treatment of a thrombus (see abstract and column 6, lines 14-24, in particular.)

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abigail M. Cotton whose telephone number is (571) 272-8779. The examiner can normally be reached on 9:30-6:00, M-F. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMC



SREENI PADMANABHAN  
SUPERVISORY PATENT EXAMINER